Atelvia FDA Approval History
FDA Approved: Yes (First approved October 8, 2010)
Brand name: Atelvia
Generic name: risedronate sodium
Dosage form: Delayed-Release Tablets
Company: Warner Chilcott
Treatment for: Osteoporosis
Atelvia (risedronate sodium) is a bisphosphonate in a delayed-release formulation for treatment of postmenopausal osteoporosis.
Development timeline for Atelvia
| Date | Article |
|---|---|
| Oct 11, 2010 | Approval Warner Chilcott Announces FDA Approval of Atelvia - Next Generation Actonel |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
